In vitro degradation of insulin-loaded poly (n-butylcyanoacrylate) nanoparticles

被引:64
作者
Sullivan, CO [1 ]
Birkinshaw, C [1 ]
机构
[1] Univ Limerick, Dept Mat Sci, Limerick, Ireland
关键词
drug delivery systems; drug release; biodegradation; poly (n-butylcyanoacrylate) nanoparticles; insulin; esterase;
D O I
10.1016/j.biomaterials.2003.11.001
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Poly (n-butyl cyanoacrylate) (PBCA) nanoparticles were prepared by a dispersion polymerisation process in water at pH 3 and using dextran as a stabilising agent. The drug insulin was introduced during the latter stages of particle synthesis and was found not to interfere with the polymer structure, molecular weight, and the particle size. Nanoparticles were exposed to the enzyme esterase in phosphate buffered saline solution at 37degreesC for time periods up to 4h. Esterase catalyses the degradation of the PBCA through hydrolysis of the side chain on the repeat unit with the release of butanol, and this was monitored as an indicator of degradation. The release of both butanol and insulin occurred via similar biphasic processes, with an initial burst release from the surface, followed by a slower diffusionally hindered release associated with particle erosion. Hydrolysis of the nanoparticle polymer was confirmed by infrared spectroscopy. Particle size reduces with time of exposure to esterase, but is greatest in the first 30 min of exposure. Despite the hydrolysis reaction, and reduction in particle size, there was no reduction in residual polymer molecular weight suggesting a progressive loss of entire chains from the active surface. Polymer loss is thought to occur through either solvation of degradation residue or through complete depolymerisation of hydrolysed chains. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4375 / 4382
页数:8
相关论文
共 18 条
[1]   Physico-chemical characterization of insulin-loaded poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization [J].
Aboubakar, M ;
Puisieux, F ;
Couvreur, P ;
Vauthier, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 183 (01) :63-66
[2]  
Behan N, 2001, MACROMOL RAPID COMM, V22, P41, DOI 10.1002/1521-3927(20010101)22:1<41::AID-MARC41>3.0.CO
[3]  
2-B
[4]   THE THERMAL-DEGRADATION OF POLYMERS OF N-BUTYLCYANOACRYLATE PREPARED USING TERTIARY PHOSPHINE AND AMINE INITIATORS [J].
BIRKINSHAW, C ;
PEPPER, DC .
POLYMER DEGRADATION AND STABILITY, 1986, 16 (03) :241-259
[5]   ADSORPTION OF ANTI-NEOPLASTIC DRUGS TO POLYALKYLCYANOACRYLATE NANOPARTICLES AND THEIR RELEASE IN CALF SERUM [J].
COUVREUR, P ;
KANTE, B ;
ROLAND, M ;
SPEISER, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (12) :1521-1524
[6]   POLYCYANOACRYLATE NANOCAPSULES AS POTENTIAL LYSOSOMOTROPIC CARRIERS - PREPARATION, MORPHOLOGICAL AND SORPTIVE PROPERTIES [J].
COUVREUR, P ;
KANTE, B ;
ROLAND, M ;
GUIOT, P ;
BAUDUIN, P ;
SPEISER, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (05) :331-332
[7]  
Couvreur P., 1980, ACTA PHARM TECHNOL, V26, P220
[8]   Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin [J].
Damge, C ;
Vranckx, H ;
Balschmidt, P ;
Couvreur, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (12) :1403-1409
[9]   NEW APPROACH FOR ORAL-ADMINISTRATION OF INSULIN WITH POLYALKYLCYANOACRYLATE NANOCAPSULES AS DRUG CARRIER [J].
DAMGE, C ;
MICHEL, C ;
APRAHAMIAN, M ;
COUVREUR, P .
DIABETES, 1988, 37 (02) :246-251
[10]   Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF) [J].
Gibaud, S ;
Rousseau, C ;
Weingarten, C ;
Favier, R ;
Douay, L ;
Andreux, JP ;
Couvreur, P .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (1-2) :131-139